search
Back to results

Assess the Safety, Tolerability Oral PU-H71 in Subjects Taking Ruxolitinib

Primary Purpose

Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF)

Status
Terminated
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
PU-H71
Sponsored by
Samus Therapeutics, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Primary Myelofibrosis (PMF) focused on measuring Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF)

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Subject is willing and able to provide written informed consent before any study-specific procedures are performed.
  2. Subject is willing to comply with all study procedures and restrictions.
  3. Subject is ≥18 years of age.
  4. Subject has confirmed diagnosis of PMF, Post-PV MF, or Post-ET MF.
  5. Subject has been receiving ruxolitinib therapy meeting the following criteria:

    • Receiving ruxolitinib >3 months prior to enrollment.
    • Stable dose for 8 weeks before starting therapy with PU-H71.
  6. Subject with evidence of evaluable residual burden of disease following ruxolitinib monotherapy treatment, consisting of:

    • Persistent or worsening disease-related symptoms, including but not limited to fatigue, pruritus, night sweats, early satiety, and other symptoms as determined by a Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score (MPN-SAF TSS) score of >12 points.

    AND

    • Documented splenomegaly of at least 5 cm below the costal margin as measured on inspiration by physical examination.

  7. Subject has an Eastern Cooperative Oncology Group performance status of 0 to 2.
  8. Acceptable pre-study organ function during screening defined as:

    • Absolute neutrophil count (ANC) ≥1000/µL.
    • Platelet count ≥50,000/µL.
    • Alanine aminotransferase or aspartate aminotransferase ≤2×upper limit of normal.
    • Direct serum bilirubin ≤ 1.5×upper limit of normal.
    • Creatinine clearance >50 mL/min/1.73 m2 based on the Cockcroft Gault equation.
  9. If female and of childbearing potential (premenopausal and not surgically sterile), the subject:

    • Must have a negative serum or urine pregnancy test at screening. The serum pregnancy test must be obtained prior to the first administration of PU-H71 (≤72 hours prior to dosing) in all premenopausal women and women <2 years after the onset of menopause.
    • Must agree to use an acceptable method of effective contraception for the duration of the study and for 13 weeks after receiving the last dose of study treatment.
  10. If male, the subject agrees to:

    • Use an acceptable method of effective contraception for the duration of the study and for 13 weeks after receiving study treatment.
    • Agrees to abstain from sperm donation for the duration of the study and for 13 weeks after receiving the last dose of study treatment

Exclusion Criteria:

  1. Subject has known active liver disease, including viral hepatitis or cirrhosis.
  2. Subject has known or suspected human immunodeficiency virus (HIV) or other active infections requiring acute or chronic treatment with systemic antibiotics. Conditions requiring topical antibiotics are acceptable.
  3. Subject has a QT interval corrected using Fridericia's formula (QTcF) >480 ms (corrected) in the screening or baseline ECG based on median value of ECG's obtained.
  4. Subject has left ventricular ejection fraction (LVEF) ≤50%, or below institution's lower limit of normal (whichever is lower), by echocardiogram or multigated acquisition (MUGA) scan.
  5. Subject has a history (or family history) of long QT syndrome.
  6. Subject has coronary artery disease with an ischemic event within 6 months prior to screening.
  7. Subject has a permanent cardiac pacemaker.
  8. Subject has history of a second primary malignancy within the past 2 years, except for the following (if appropriately treated and considered cured): Stage I endometrial, surgically treated cervical or prostate carcinoma, and non-melanoma skin cancer.
  9. Subject has significant uncontrolled medical condition within 6 months prior to screening, as determined by the Investigator.
  10. Subject has planned use of antineoplastic agents (chemotherapy or cytotoxic drugs), immunotherapy, experimental therapy, or biologic therapy for treatment of MPN with the exception of ruxolitinib.
  11. Subject uses systemic corticosteroids (ie, prednisone >12.5 mg/day or dexamethasone >2 mg/day) within 2 weeks prior to Cycle 1 Day 1.
  12. Subject has planned or current use of strong CYP3A4/5, CYP2D6, or CYP2C19 inhibitors or inducers within 1 week or 5 half-lives (whichever is longer) prior to Cycle 1 Day 1.
  13. Subject has planned or current use of medications that carry a risk for Torsades de Pointes within 1 week or 5 half-lives (whichever is longer) prior to Cycle 1 Day 1.
  14. Subject has planned or current use of herbal preparations/medications at least 7 days prior to Cycle 1 Day 1.
  15. Subject has previously received PU-H71.
  16. Subject has concurrent participation in any interventional studies (except PU-H71-Positive Emission Tomography (PET) Scan Studies) within 14 days or 5 half-lives (whichever duration is longer) of Cycle 1 Day 1.
  17. Subject has uncontrolled diabetes mellitus, in the judgment of the Investigator.
  18. Subject has any other condition or laboratory abnormality or receives any other treatment(s) that may increase the risk associated with study participation or may interfere with the interpretation of study results in the judgment of the Investigator.
  19. Subject has an active ocular condition that in the opinion of the Investigator, may alter visual acuity during the course of the study (ie, ocular inflammatory disease, etc.) or a history or anticipation of major ocular surgery (including cataract extraction, intraocular surgery, etc.) during the study.
  20. Women who are pregnant or breastfeeding or plan to become pregnant.

Sites / Locations

  • Marin Cancer Care - Greenbrae (California Cancer Care A Medical Group, Inc. - Greenbrae)
  • Ronald Reagan UCLA Medical Center
  • MD Anderson

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

Experimental

Experimental

Experimental

Arm Label

Oral - 50mg

Oral -100 mg

Oral - 200 mg

Oral - 300 mg

Arm Description

PU-H71 (a small molecule purine-scaffold epichaperome inhibitor selective for stress-induced HSP90 in epichaperomes).

PU-H71 (a small molecule purine-scaffold epichaperome inhibitor selective for stress-induced HSP90 in epichaperomes).

PU-H71 (a small molecule purine-scaffold epichaperome inhibitor selective for stress-induced HSP90 in epichaperomes).

PU-H71 (a small molecule purine-scaffold epichaperome inhibitor selective for stress-induced HSP90 in epichaperomes).

Outcomes

Primary Outcome Measures

Assess Safety, Tolerability and Pharmacokinetics of PU-H71
Determine the human exposure PK including Cmax
Assess Safety, Tolerability and Pharmacokinetics of PU-H71
Determine the human exposure PK including Tmax
Assess Safety, Tolerability and Pharmacokinetics of PU-H71
Determine the human exposure PK including AUC0-t
Assess Safety, Tolerability and Pharmacokinetics of PU-H71
Determine the human exposure PK including AUC0-inf
Assess Safety, Tolerability and Pharmacokinetics of PU-H71
Determine the human exposure PK including CL
Assess Safety, Tolerability and Pharmacokinetics of PU-H71
Determine the human exposure PK including t1/2
Assess Safety and Tolerability of PU-H71
Determine the Incidence and severity of AEs as determined by the NCI-CTCAE Version 5.0 and by changes in physical examinations
Assess Safety and Tolerability of PU-H71
Determine the Incidence and severity of AEs as determined by the NCI-CTCAE Version 5.0 and by changes in electrocardiograms (ECGs)
Assess Safety and Tolerability of PU-H71
Determine the Incidence and severity of AEs as determined by the NCI-CTCAE Version 5.0 and by changes in vital signs
Assess Safety and Tolerability of PU-H71
Determine the Incidence and severity of AEs as determined by the NCI-CTCAE Version 5.0 and by changes in clinical laboratory evaluations
Assess treatment response of PU H71
Treatment response in myelofibrosis (MF) is to be evaluated using the revised International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT)
Assess treatment response of PU H71
Treatment response in myelofibrosis (MF) is to be evaluated using the revised European LeukemiaNet (ELN) response criteria.

Secondary Outcome Measures

Full Information

First Posted
March 14, 2019
Last Updated
November 14, 2022
Sponsor
Samus Therapeutics, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT03935555
Brief Title
Assess the Safety, Tolerability Oral PU-H71 in Subjects Taking Ruxolitinib
Official Title
Phase 1b Study of PU-H71 for the Treatment of Subjects With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Treated With Ruxolitinib
Study Type
Interventional

2. Study Status

Record Verification Date
November 2022
Overall Recruitment Status
Terminated
Why Stopped
Samus Therapeutics company closure
Study Start Date
August 12, 2019 (Actual)
Primary Completion Date
October 19, 2022 (Actual)
Study Completion Date
November 4, 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Samus Therapeutics, Inc.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This is a multicenter, Phase 1b study with dose escalation and expansion cohorts designed to assess the safety, tolerability, PK, and preliminary efficacy of PU-H71 in subjects with PMF, Post-PV MF, Post-ET MF, taking stable doses of ruxolitinib.
Detailed Description
The study will employ a standard 3+3 dose escalation design to determine maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), with additional subjects treated in a dose expansion cohort. The time period for collecting dose limiting toxicities (DLTs) is 1 cycle (21 days).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF)
Keywords
Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF)

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Sequential Assignment
Model Description
The study will employ a standard 3+3 dose escalation design to determine maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), with additional subjects treated in a dose expansion cohort. The time period for collecting dose limiting toxicities (DLTs) is 1 cycle (21 days).
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
11 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Oral - 50mg
Arm Type
Experimental
Arm Description
PU-H71 (a small molecule purine-scaffold epichaperome inhibitor selective for stress-induced HSP90 in epichaperomes).
Arm Title
Oral -100 mg
Arm Type
Experimental
Arm Description
PU-H71 (a small molecule purine-scaffold epichaperome inhibitor selective for stress-induced HSP90 in epichaperomes).
Arm Title
Oral - 200 mg
Arm Type
Experimental
Arm Description
PU-H71 (a small molecule purine-scaffold epichaperome inhibitor selective for stress-induced HSP90 in epichaperomes).
Arm Title
Oral - 300 mg
Arm Type
Experimental
Arm Description
PU-H71 (a small molecule purine-scaffold epichaperome inhibitor selective for stress-induced HSP90 in epichaperomes).
Intervention Type
Drug
Intervention Name(s)
PU-H71
Intervention Description
PU-H71 is a synthetic purine-scaffold stress chaperome inhibitor, which specifically targets HSP90 in the tumor-specific epichaperome
Primary Outcome Measure Information:
Title
Assess Safety, Tolerability and Pharmacokinetics of PU-H71
Description
Determine the human exposure PK including Cmax
Time Frame
24 weeks
Title
Assess Safety, Tolerability and Pharmacokinetics of PU-H71
Description
Determine the human exposure PK including Tmax
Time Frame
24 weeks
Title
Assess Safety, Tolerability and Pharmacokinetics of PU-H71
Description
Determine the human exposure PK including AUC0-t
Time Frame
24 weeks
Title
Assess Safety, Tolerability and Pharmacokinetics of PU-H71
Description
Determine the human exposure PK including AUC0-inf
Time Frame
24 weeks
Title
Assess Safety, Tolerability and Pharmacokinetics of PU-H71
Description
Determine the human exposure PK including CL
Time Frame
24 weeks
Title
Assess Safety, Tolerability and Pharmacokinetics of PU-H71
Description
Determine the human exposure PK including t1/2
Time Frame
24 weeks
Title
Assess Safety and Tolerability of PU-H71
Description
Determine the Incidence and severity of AEs as determined by the NCI-CTCAE Version 5.0 and by changes in physical examinations
Time Frame
24 weeks
Title
Assess Safety and Tolerability of PU-H71
Description
Determine the Incidence and severity of AEs as determined by the NCI-CTCAE Version 5.0 and by changes in electrocardiograms (ECGs)
Time Frame
24 weeks
Title
Assess Safety and Tolerability of PU-H71
Description
Determine the Incidence and severity of AEs as determined by the NCI-CTCAE Version 5.0 and by changes in vital signs
Time Frame
24 weeks
Title
Assess Safety and Tolerability of PU-H71
Description
Determine the Incidence and severity of AEs as determined by the NCI-CTCAE Version 5.0 and by changes in clinical laboratory evaluations
Time Frame
24 weeks
Title
Assess treatment response of PU H71
Description
Treatment response in myelofibrosis (MF) is to be evaluated using the revised International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT)
Time Frame
24 weeks
Title
Assess treatment response of PU H71
Description
Treatment response in myelofibrosis (MF) is to be evaluated using the revised European LeukemiaNet (ELN) response criteria.
Time Frame
24 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Subject is willing and able to provide written informed consent before any study-specific procedures are performed. Subject is willing to comply with all study procedures and restrictions. Subject is ≥18 years of age. Subject has confirmed diagnosis of PMF, Post-PV MF, or Post-ET MF. Subject has been receiving ruxolitinib therapy meeting the following criteria: Receiving ruxolitinib >3 months prior to enrollment. Stable dose for 8 weeks before starting therapy with PU-H71. Subject with evidence of evaluable residual burden of disease following ruxolitinib monotherapy treatment, consisting of: • Persistent or worsening disease-related symptoms, including but not limited to fatigue, pruritus, night sweats, early satiety, and other symptoms as determined by a Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score (MPN-SAF TSS) score of >12 points. AND • Documented splenomegaly of at least 5 cm below the costal margin as measured on inspiration by physical examination. Subject has an Eastern Cooperative Oncology Group performance status of 0 to 2. Acceptable pre-study organ function during screening defined as: Absolute neutrophil count (ANC) ≥1000/µL. Platelet count ≥50,000/µL. Alanine aminotransferase or aspartate aminotransferase ≤2×upper limit of normal. Direct serum bilirubin ≤ 1.5×upper limit of normal. Creatinine clearance >50 mL/min/1.73 m2 based on the Cockcroft Gault equation. If female and of childbearing potential (premenopausal and not surgically sterile), the subject: Must have a negative serum or urine pregnancy test at screening. The serum pregnancy test must be obtained prior to the first administration of PU-H71 (≤72 hours prior to dosing) in all premenopausal women and women <2 years after the onset of menopause. Must agree to use an acceptable method of effective contraception for the duration of the study and for 13 weeks after receiving the last dose of study treatment. If male, the subject agrees to: Use an acceptable method of effective contraception for the duration of the study and for 13 weeks after receiving study treatment. Agrees to abstain from sperm donation for the duration of the study and for 13 weeks after receiving the last dose of study treatment Exclusion Criteria: Subject has known active liver disease, including viral hepatitis or cirrhosis. Subject has known or suspected human immunodeficiency virus (HIV) or other active infections requiring acute or chronic treatment with systemic antibiotics. Conditions requiring topical antibiotics are acceptable. Subject has a QT interval corrected using Fridericia's formula (QTcF) >480 ms (corrected) in the screening or baseline ECG based on median value of ECG's obtained. Subject has left ventricular ejection fraction (LVEF) ≤50%, or below institution's lower limit of normal (whichever is lower), by echocardiogram or multigated acquisition (MUGA) scan. Subject has a history (or family history) of long QT syndrome. Subject has coronary artery disease with an ischemic event within 6 months prior to screening. Subject has a permanent cardiac pacemaker. Subject has history of a second primary malignancy within the past 2 years, except for the following (if appropriately treated and considered cured): Stage I endometrial, surgically treated cervical or prostate carcinoma, and non-melanoma skin cancer. Subject has significant uncontrolled medical condition within 6 months prior to screening, as determined by the Investigator. Subject has planned use of antineoplastic agents (chemotherapy or cytotoxic drugs), immunotherapy, experimental therapy, or biologic therapy for treatment of MPN with the exception of ruxolitinib. Subject uses systemic corticosteroids (ie, prednisone >12.5 mg/day or dexamethasone >2 mg/day) within 2 weeks prior to Cycle 1 Day 1. Subject has planned or current use of strong CYP3A4/5, CYP2D6, or CYP2C19 inhibitors or inducers within 1 week or 5 half-lives (whichever is longer) prior to Cycle 1 Day 1. Subject has planned or current use of medications that carry a risk for Torsades de Pointes within 1 week or 5 half-lives (whichever is longer) prior to Cycle 1 Day 1. Subject has planned or current use of herbal preparations/medications at least 7 days prior to Cycle 1 Day 1. Subject has previously received PU-H71. Subject has concurrent participation in any interventional studies (except PU-H71-Positive Emission Tomography (PET) Scan Studies) within 14 days or 5 half-lives (whichever duration is longer) of Cycle 1 Day 1. Subject has uncontrolled diabetes mellitus, in the judgment of the Investigator. Subject has any other condition or laboratory abnormality or receives any other treatment(s) that may increase the risk associated with study participation or may interfere with the interpretation of study results in the judgment of the Investigator. Subject has an active ocular condition that in the opinion of the Investigator, may alter visual acuity during the course of the study (ie, ocular inflammatory disease, etc.) or a history or anticipation of major ocular surgery (including cataract extraction, intraocular surgery, etc.) during the study. Women who are pregnant or breastfeeding or plan to become pregnant.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Michael Silverman, M.D.
Organizational Affiliation
Samus Therapeutics
Official's Role
Study Director
Facility Information:
Facility Name
Marin Cancer Care - Greenbrae (California Cancer Care A Medical Group, Inc. - Greenbrae)
City
Larkspur
State/Province
California
ZIP/Postal Code
94904
Country
United States
Facility Name
Ronald Reagan UCLA Medical Center
City
Los Angeles
State/Province
California
ZIP/Postal Code
90095
Country
United States
Facility Name
MD Anderson
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Assess the Safety, Tolerability Oral PU-H71 in Subjects Taking Ruxolitinib

We'll reach out to this number within 24 hrs